Galenica (GALE) Q4 2025 TU earnings summary

Executive summary

• Net sales reached CHF 4,135.6 million in 2025, up 5.5% year-over-year, marking a record high despite one fewer sales day compared to 2024.

• Growth was broad-based, supported by the acquisition of Labor Team, expansion in local pharmacies, and strong demand for prescription medicines and dietary supplements.

• The new Diagnostics business area contributed 1% to overall sales growth.

Financial highlights

• Net sales increased from CHF 3,921.1 million in 2024 to CHF 4,135.6 million in 2025 (+5.5%).

• EBIT guidance for 2025 confirmed at a 10-12% increase, following the Labor Team acquisition.

• Dividend expected to at least match the previous year's level.

• Products & Care segment grew 6.8% to CHF 1,816.4 million; Logistics & IT up 4.8% to CHF 3,332.6 million.

• Pharmacies Omni-Channel sales rose 4.9% to CHF 1,473.3 million; Wholesale up 4.8% to CHF 3,255.3 million.

Outlook and guidance

• EBIT is expected to increase by 10-12% in 2025, excluding certain accounting effects.

• Forward-looking statements highlight risks from market demand, competition, and technology changes.

• Dividend payout is anticipated to be at least at the previous year's level.